Anti-aging pharmacology: Promises and pitfalls

Vaiserman, Alexander; Lushchak, Oleh; Koliada, Alexander

doi:10.1016/j.arr.2016.08.004

Cited by 116 publications

(102 citation statements)

References 406 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…Presently, however, due to insufficient knowledge regarding the potential side effects of these technologies, including cancer, uncertainties and concerns still prevail about their safety among the general public and medical professionals. Therefore, the use of more traditional pharmacological interventions can be considered as a reasonable alternative now [35]. …”

Section: Introductionmentioning

confidence: 99%

“…Substantial progress has been, however, achieved during recent years in this field of investigation. Some classes of chemically synthesized compounds and nutraceuticals were identified as having potential for anti-aging intervention [4, 35]. Several substances capable of mimicking the effects of calorie restriction, such as rapamycin, resveratrol and metformin, are thought to be among the most promising in this respect now [39] In addition, high hopes are placed by some authors on antioxidants (coenzyme Q10, quercetin, melatonin, vitamins A, C and E, etc.)…”

Section: Introductionmentioning

confidence: 99%

“…[43], and also several other natural and synthesized compounds. All these substances have been shown to be able to extend lifespan up to 25–30% in different animal models [35]. Over the last years, biotechnological applications are widely used in anti-aging pharmacology.…”

Section: Introductionmentioning

confidence: 99%

“…Only agents that have reached clinical trials for treating various age-associated clinical conditions are included in the table. The most comprehensive to date overview of the current state-of-the-art in the field of anti-aging pharmacology is provided in recent paper by Vaiserman et al [35]. …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Implementation of longevity-promoting supplements and medications in public health practice: achievements, challenges and future perspectives

Vaiserman

Lushchak

2017

J Transl Med

View full text Add to dashboard Cite

BackgroundMost modern societies undergo rapid population aging. The rise in life expectancy, nevertheless, is not accompanied, to date, by the same increment of healthspan. Efforts to increase healthspan by means of supplements and pharmaceuticals targeting aging-related pathologies are presently in spotlight of a new branch in geriatric medicine, geroscience, postulating that aging could be manipulated in such a way that will in parallel allow delay the onset of all age-associated chronic disorders.DiscussionCurrently, the concept of the “longevity dividend” has been developed pointed out that the extension of healthspan by slowing the rate of aging is the most efficient way to combat various aging-related chronic illnesses and disabling conditions than combating them one by one, what is the present-day approach in a generally accepted disease-based paradigm. The further elaboration of pharmaceuticals specifically targeted at age-associated disorders (commonly referred to as ‘anti-aging drugs’) is currently one of the most extensively developed fields in modern biogerontology. Some classes of chemically synthesized compounds and nutraceuticals such as calorie restriction mimetics, autophagy inductors, senolytics and others have been identified as having potential for anti-aging intervention through their possible effects on basic processes underlying aging. In modern pharmaceutical industry, development of new classes of anti-aging medicines is apparently one of the most hopeful directions since potential target group may include each adult individual.SummaryImplementation of the geroscience-based approaches into healthcare policy and practice would increase the ratio of healthy to unhealthy population due to delaying the onset of age-associated chronic pathologies. That might result in decreasing the biological age and increasing the age of disability, thus increasing the age of retirement and enhancing income without raising taxes. Economic, social and ethical aspects of applying the healthspan- and lifespan-promoting interventions, however, have to be comprehensively debated prior to their implementation in public health practice.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Implementation of longevity-promoting supplements and medications in public health practice: achievements, challenges and future perspectives

Vaiserman

Lushchak

2017

J Transl Med

View full text Add to dashboard Cite

show abstract

“…To highlight strategies with greatest potential to manipulate human ageing, only drugs that have demonstrable effects in mammals will be considered. Other reviews have covered longevity-enhancing treatments in non-mammalian models (Vaiserman and Marotta, 2016, Vaiserman et al, 2016). …”

Section: Introductionmentioning

confidence: 99%

Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks

Mallikarjun

Swift

2016

EBioMedicine

View full text Add to dashboard Cite

Ageing is a leading risk factor for many debilitating diseases. While age-related diseases have been the subject of over a century of intense investigation, until recently, physiological ageing was considered unavoidable. Pharmacological and genetic studies have since shown that ageing is a malleable process and that its abrogation can prevent its associated diseases. This review summarises a sample of the most promising efforts to deliver the products of ageing research to the clinic. Current efforts include the use of clinically approved drugs that have since been repurposed, as well as the development of novel therapeutics, to target ageing. Furthermore, ongoing research has sought reliable biomarkers of ageing that will accelerate the development of such therapeutics. Development of these technologies will improve quality of late-life and help relieve the enormous stress placed on state healthcare systems by a rapidly ageing global population. Thus, for both medical and socioeconomic reasons, it is imperative that ageing is made to yield to intervention.

show abstract

Ageing Genes: Gerontogenes

Rattan

2018

Encyclopedia of Life Sciences

View full text Add to dashboard Cite

The idea of gerontogenes is in line with the evolutionary explanation of ageing as being an emergent phenomenon as a result of the imperfect maintenance and repair systems. Although evolutionary processes did not select for any specific ageing genes that restrict and determine the lifespan of an individual, the term ‘gerontogenes’ primarily refers to any genes that may seem to influence ageing and longevity, without being specifically selected for that role. Such genes can also be called ‘virtual gerontogenes’ by virtue of their indirect influence on the rate and process of ageing. More than 1000 virtual gerontogenes have been associated with ageing and longevity in model organisms and humans. The ‘real’ genes, which do influence the essential lifespan of a species, and have been selected for in accordance with the evolutionary life history of the species, are known as the longevity assurance genes. Key Concepts Biological ageing is a progressive decline in functional ability and an increase in the chances of frailty, diseases and death. Ageing can be considered to set in mainly after the completion of the essential lifespan (ELS) of a species. ELS is the duration of time required by a species in its natural environment in order to grow, develop, mature and reproduce. Evolution has selected for longevity assurance genes (LAG) that determine ELS of a species. Genetic pathways of maintenance and repair are the basis of LAG, and give rise to the homeodynamic space of an individual within a species. Ageing is the progressive shrinkage of the homeodynamic space. Evolution has not selected for any genes with the specific function of causing ageing and terminating the life of an individual. Ageing, age‐related diseases and death are not programmed. Genes for ageing – gerontogenes – is a conceptual term for discussing the involvement of genes in affecting the rate and extent of ageing. Gerontogenes are not real; they are, at best, virtual in the sense that LAG become altered because of molecular damage and epigenetic alterations. Hundreds of putative virtual gerontogenes have been associated with the longevity of model organisms and humans. Eliminating ageing and death by gene therapy is at present only a wishful thinking.

show abstract

Anti-aging pharmacology: Promises and pitfalls

Cited by 116 publications

References 406 publications

Implementation of longevity-promoting supplements and medications in public health practice: achievements, challenges and future perspectives

Implementation of longevity-promoting supplements and medications in public health practice: achievements, challenges and future perspectives

Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks

Ageing Genes: Gerontogenes

Contact Info

Product

Resources

About